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ABSTRACT
Specific detection of mRNA cleavage by 50RACE
is the only method to confirm the knockdown
of mRNA by RNA interference, but is rarely
reported for in vivo studies. We have combined
50-RNA-linker-mediated RACE (50-RLM-RACE) with
real-time PCR using a molecular beacon to
develop a rapid and specific method termed
MBRACE, which we have used to detect small-
interfering RNA (siRNA)-induced cleavage of ApoB,
RRM1 and YBX1 transcripts in vitro, and ApoB
in vivo. When RNA from siRNA-transfected cells
was used for 50-RLM-RACE and a cleavage site-
specific molecular beacon probe was included in
subsequent real-time PCR analysis, the specific
mRNA cleavage product was detected. Detection
of siRNA-mediated cleavage was also observed
when RNA from mouse liver following administra-
tion of ApoB-specific siRNA was analysed, even in
cases where ApoB knockdown measured by
real-time PCR was <10%. With its sensitivity and
specificity, this variation on the 50RACE method
should prove a useful tool to detect mRNA
cleavage and corroborate knockdown studies fol-
lowing siRNA use in vivo.
INTRODUCTION
The inhibition of gene expression by RNAi has great ther-
apeutic potential but remains hampered by ineﬃcient
delivery of siRNA and potential oﬀ-target eﬀects.
Although many avenues of delivery are being investigated,
including the use of localised delivery by direct injection
and topical administration, and systemic delivery with
intravenous administration (1–3) very few studies have
included data to conﬁrm that the eﬀects of siRNA
observed in vivo are due to an RNAi-mediated mRNA
cleavage mechanism rather than non-speciﬁc events.
siRNAs have the potential to trigger an innate immune
response through the activation of Toll-like receptors
(TLR 3, 7 and 8) and also by binding to proteins such
as retinoic acid inducible gene 1, and this itself may cause
a modulation in gene expression which could account
for the observed eﬀects attributed to siRNA-mediated
RNAi (4,5).
The importance of conﬁrming that mRNA knock-
down following siRNA administration has occurred
via an RNAi-mediated event is highlighted by two
recent studies reporting the considerable contribution
of the innate immune system to apparent in vivo knock-
down, suggesting that many of the reports of in vivo
eﬃcacy of siRNAs can be explained by a general
down-regulation of transcription that is stimulated by
the double stranded RNA structure of siRNA with-
out involving RNAi. Kleinman et al. (6) demon-
strated that the intravitreal injection of siRNA could
lead to down regulation of vascular endothelial growth
factor a (Vegfa) and its receptor (Vegfr1) in a
sequence-independent manner, as siRNAs with no
homology to Vegfa or Vegfr1 were as eﬀective as
speciﬁc siRNAs (6). More recently, it was demon-
strated that siRNAs able to inhibit viral replication
in vivo do so via stimulation of the innate immune
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and that the negative control used in these studies had
an unusually low immunostimulatory activity, and had
also been a component of several other in vivo studies
assessing immunostimulatory siRNA.
Conﬁrmation that an observed mRNA knockdown
has occured via an RNAi-based cleavage event can be
demonstrated using the well-established technique of
Rapid Ampliﬁcation of cDNA Ends (RACE), as
siRNAs cleave their target sequence following a canonical
pattern 10bp from the 50-end of the antisense strand (8,9).
The slicing action of the RISC-associated Argonaute 2
protein at this position cleaves the target mRNA into
two distinct fragments: a 50 fragment with a 30 hydroxyl
group, and a 30 fragment with a 50 phosphate. Either of
these fragments can be ampliﬁed using RACE in a
modiﬁed version of the RLM-RACE protocol (10,11).
The ampliﬁed fragment must then be cloned and
sequenced to ascertain the junction between the RNA
linker sequence and the target RNA sequence which, if
mRNA cleavage has occurred via RNAi, should correlate
with the position as predicted by the siRNA sequence
(12–17). Although RACE-based detection has been
utilised to assess the action of antisense-based inhibition
of expression (18), it has only rarely been used in the cor-
roboration of knockdown data observed in an ever
increasing range of studies using RNAi in vivo (12–17).
This may be because RLM-RACE appears to be an inef-
ﬁcient process for detecting mRNA cleavage products,
despite the inherent speciﬁcity of using target and
linker-speciﬁc primers. In standard 50-RLM-RACE, a
dephosphorylation step is used to remove any RNAs
that have a 50phosphate (including nicked transcripts),
eﬀectively enriching for the capped full-length mRNA,
which can then be de-capped and ligated. To detect
siRNA-cleaved transcripts, which are also phosphorylated
RNAs, this enrichment step cannot be performed;
hence any nicked RNAs are also ampliﬁed thereby
decreasing the eﬃciency and sensitivity of the reaction.
Sequence analysis of this heterogenous population of
amplicons determines if a correct product has been
derived from the siRNA-mediated cleavage of the target
transcript.
In order to overcome these problems, we have modiﬁed
the second PCR of 50-RLM-RACE ampliﬁcation to be
a real-time PCR using a molecular beacon hybrid-
isation probe (19) speciﬁc to the junction between
the RNA linker and mRNA cleavage site. The speciﬁcity
of molecular beacon probes has been well proven to
distinguish between sequence alterations of one nucleo-
tide (20), enabling their use in an expanding ﬁeld of
hybridisation-based applications (21). This high degree
of speciﬁcity means the junction region between the
RNA linker sequence and the cleaved siRNA site can be
detected in real-time, eliminating the need to run further
nested PCR reactions, clone the candidate amplicons and
then conﬁrm their identity via sequencing. We have used
this method to detect siRNA-mediated cleavage of ApoB,
RRM1 and YBX1 transcripts in vitro, and also of ApoB
in vivo.
MATERIALS AND METHODS
Primers, siRNAs and molecular beacon probes
The sequences of the primers, siRNAs and molecular
beacons used are detailed in Table 1. RRM1 and YBX1
siRNAs and all primers for qPCR were from Invitrogen
Corporation (Carlsbad, CA, USA). The ApoB-speciﬁc
siRNA ApoB-1 and a mismatched control siRNA were
of identical sequence to those used by Alnylam (12), and
were synthesised by TriLink Biotechnologies (Carlsbad).
The primers and probes for the MBRACE assays were
designed using Beacon Designer
TM from PREMIER
Biosoft International (Palo Alto, CA, USA). MBRACE
primers were purchased from Invitrogen and the molecu-
lar beacon probes were synthesised by Integrated DNA
Technologies, Inc. (Coralville, IA, USA).
Cell lines and transfection
The Hepa1-6 and A549 cell lines used in this study were
obtained from ATCC. Hepa1-6 cells were grown in
DMEM and A549 cells in RPMI-1640 medium, both sup-
plemented with 10% heat-inactivated fetal bovine serum
(FBS) (all from Invitrogen), at 37 C in humidiﬁed air with
10% CO2. To measure siRNA-mediated knockdown, cells
were transfected with speciﬁc or control siRNAs using
Lipofectamine
TM RNAiMAX (Invitrogen) as per the
manufacturer’s instructions with modiﬁcations (22).
Brieﬂy, siRNAs and Lipofectamine
TM RNAiMax were
diluted in DMEM or RPMI 1640 without serum, and
incubated for 5–10min at room temperature. The
diluted RNAiMAX was added drop-wise to the siRNA,
and lipoplex formation was allowed to proceed for
20–30min at room temperature. Lipoplexes were then
transferred to multi-well tissue culture plates and
overlaid with 5 10
3 cells per cm
2. Following overnight
incubation, cells were isolated and mRNA knockdown
was measured as described below.
Isolation of RNA
For in vitro samples, RNA was isolated using the
PureLink
TM 96 RNA Puriﬁcation system as per the man-
ufacturer’s protocol (Invitrogen). For in vivo samples,
tissue was homogenised in 2ml Trizol (Invitrogen),
debris removed by centrifugation and samples divided
into 2 1ml aliquots. To each aliquot, 0.2ml chloroform
was added followed by centrifugation. The aqueous phase
was retained and an equal volume of 70 % ethanol was
added and mixed. This was applied to the PureLink
TM 96
RNA Puriﬁcation system as above. Puriﬁed RNA quality
and concentration was assessed with a NanoDrop 1000
spectrophotometer.
Real-time RT–qPCR
First-strand cDNA was synthesised from  200ng RNA
from cultured cells or 1mg RNA from liver samples as
follows: RNA was treated with DNase I for 15min at
room temperature, followed by incubation for 10min at
65 C in the presence of 0.6mM EDTA. After the addition
of random primers (1.5mg) the reaction was incubated for
a further 10min at 65 C. After cooling on ice for 1min,
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presence of 5mM DTT and 1mM dNTPs, and the
reaction incubated at 25 C for 5min, followed by 1h at
55 C. For real-time PCR, the cDNA was diluted 1:4 in
10mM Tris pH 7.0, and reactions carried out on a
LightCycler 480 (Roche) using LightCycler 480
SybrGreen I Master mix (Roche) and gene-speciﬁc
primers at 180nM. Levels of ApoB, RRM1 or YBX1
mRNA were normalised to the reference gene RNA
polymerase IIa (Polr2a) for mouse cell lines and in vivo
samples, and lamin A/C (LMNA) for human cell lines,
and relative change in mRNA following treatment with
speciﬁc or control siRNA was calculated from triplicate
technical replicates of each using the 2Ct method (23).
Standard deviations were also calculated, based on the Ct
standard deviation of the three technical replicates and
converted to fold change.
50-RLM-RACE
50-RLM-RACE was performed using the GeneRacer
TM
kit (Invitrogen) with the manufacturer’s instructions
modiﬁed as follows. Brieﬂy, 100ng total RNA was
directly ligated to the RNA linker without prior treat-
ment. After phenol/chloroform extraction and precipita-
tion, ﬁrst-strand cDNA was synthesised using a
gene-speciﬁc primer (Table 1). From this reaction, 1ml
was used in ﬁrst-round 50RACE reactions using the
GeneRacer 50 primer and target gene-speciﬁc primer
with cycling as described in the GeneRacer
TM kit man-
ual: 1 cycle of 94 C for 2min, then 5 cycles of 94 C for
30s and 72 C for 1min, then 5 cycles of 94 C for 30s and
70 C for 1min, then 20 cycles of 94 C for 30s and 68 C
for 1min. The second-round 50RACE reaction used 1mlo f
the ﬁrst-round reaction and internal primers
(GeneRacer
TM Nested and gene-speciﬁc nested) with
cycling as above but with an extension time of 15s.
From this reaction, 10ml was analysed on a 3% agarose
gel. To conﬁrm the site of mRNA cleavage, a region cor-
responding to the size of the predicted 50RACE amplicon
was excised. The DNA was cloned using the TA Cloning
kit (Life Technologies) and sequenced using an ABI3730
sequencer, with BigDyeTM Terminator 3.1 Ready
Reaction Cycling kit (Applied Biosystems, Foster City,
CA, USA).
Table 1. Sequences of siRNAs, primers and probes used in this study
siRNAs
Name Passenger strand Guide strand
ApoB-1 GUCAUCACACUGAAUACCAAU AUUGGUAUUCAGUGUGAUGAmC*mA*C
ApoB1mm control GUGAUCAGACUCAAUACGAAU AUUCGUAUUGAGUCUGAUCAmC*mA*C
RRM1-2 CCCAGUUACUGAAUAAGCAGAUCUU AAGAUCUGCUUAUUCAGUAACUGGGCU
RRM1-3 GCAAACUCACUAGUAUGCACUUCUA UAGAAGUGCAUACUAGUGAGUUUGCCU
RRM1-15 GAUUGUAAAUCCUCACUUAdTdT UAAGUGAGGAUUUACAAUCdTdT
YBX1-9 CCAGUUCAAGGCAGUAAAUdTdT AUUUACUGCCUUGAACUGGdTdT
qPCR Primers
Target Forward Reverse
ApoB GGCACTGTGGGTCTGGAT TTCTTCTCTGGAGGGGACTG
RRM1 GGCAAACTCACTAGTATGCACTTC AAATAATACATCCCAGTCTTCAAACC
YBX1 GGAGTTTGATGTTGTTGAAGGA AACTGGAACACCACCAGGAC
Polr2a TTACTCCCCTGCATGGTCTC TGGGAGACATAGCACCACCT
LMNA TGAGGCCAAGAAGCAACTTCA CTCATGACGGCGCTTGGT
Gene-speciﬁc primers for ﬁrst-strand cDNA synthesis
ApoB AGAACCCGTGATTCAACCTG
RRM1 AAGCAGTGCTAAAGGGGTGA
YBX1 CCGGATGATGGTAGAGATGG
First-round RACE gene-speciﬁc primers
ApoB GCTCCCATGTGGTGTAGATGCGTTGGA
RRM1 TGCTGCATTTGATGGTTCCCAGGTTCTG
YBX1 TCTGGGCGTCTGCGTCGGTAATTGA
MBRACE primers
Target site Forward Reverse
ApoB-1 ACTGGAGCACGAGGACACTG GGAAGAAAGGAAATGGGCAACG
RRM1-2 CGACTGGAGCACGAGGAC AGCCCTCATAGGTTTCGTATGG
RRM1-3 CGACTGGAGCACGAGGAC GATTAGCCGCTGGTCTTGTC
RRM1-15 ACTGGAGCACGAGGACAC AGGAATTTCTGGTATGCTCTG
YBX1-9 CGACTGGAGCACGAGGACAC TGCTGGTAATTGCGTGGAGGAC
Molecular beacon probes
ApoB-1 F-CGCGATCCCAGCATTGGTATTCTTTCTACTCCTTCAGATCGCG-B
RRM1-2 F-CGCGATCAAAGATCTGCTTTTCTACTCCTTCAGTCCGATCGCG-B
RRM1-3 F-CGCGATCCCGTAGAAGTGCATTTCTACTCCTTCAGATCGCG-B
RRM1-15 F-CGCGATCAGATCTTTCAATAAGTGAGGATTTCTACTCCGATCGCG-B
YBX1-9 F-CGCGATCTGCATATTTACTGCCTTTCTACTCCTTCAGATCGCG-B
All sequences are given in 50-30 orientation. The siRNA sequences are RNA except dTdT deoxynucleotides ends. The Stealth duplexes (RRM1-2 and
RRM1-3) are dsRNA with proprietary modiﬁcations of the passenger strand; m, 20-O-Methyl ribose-modiﬁed nucleotides; *phosphorothioate
linkage; F, FAM dye label; B, Black Hole Quencher.
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The ﬁrst round 50RACE reaction product described above
was used as a template for the MBRACE reaction. This
contained 1ml from the ﬁrst-round RACE reaction and
the TaqMan Probe Master (Roche). For the ﬁnal
optimised method, primers and probes were used at the
following concentrations: 180nM MB-R, 3.6mM MB-F
and 250nM molecular beacon probe (all speciﬁc for the
target gene). Reactions were run on a LightCycler 480
with the following cycling conditions: 95 C for 10min,
then 45–55 cycles of 95 C for 10s, 62 C for 30s and
72 C for 8s, followed by 40 C for 30s.
Hydrodynamic tail-vein injection
Female CD-1 nude mice, 5–6 weeks of age and weighing
20–23g were assigned to treatment groups such that the
mean body weights were similar for each group. The
animals were placed in a restraining device and injected
without anaesthesia. Fifty microgram of ApoB-1 siRNA
or the control siRNA in 1.8ml Ringer’s Solution (147mM
NaCl, 4mM KCl, 1.13mM CaCl2) was rapidly (within
5–7s) injected into one of the tail side veins through a
27-gauge needle. The injection was repeated 8 and 24h
later. Twenty-four hours after the last injection, animals
were humanely euthanised by CO2 asphyxiation and livers
collected. Liver tissues were snap-frozen in liquid nitrogen
and stored at  80 C prior to RNA isolation. Animal
experiments were performed with animal care ethics
approval by the Genesis Research and Development
Animal Ethics Committee, under Code of Ethical
Conduct approved by the National Animal Ethics
Advisory Committee and Ministry of Agriculture and
Forestry, in accordance with the New Zealand Animal
Welfare Act 1999.
RESULTS
Molecular beacon RACE detects siRNA-mediated
mRNA cleavage
Standard 50RLM-RACE can be used to conﬁrm that
mRNA knockdown as measured by real-time RT–qPCR
is the result of speciﬁc siRNA-directed cleavage of mRNA
directed by siRNAs, but it is time consuming and rarely
carried out. To improve the speed and sensitivity of the
50-RLM-RACE assay, we modiﬁed the method to allow
sequence-speciﬁc ﬂuorescence-based detection of the
cleaved target mRNA. This involved addition of an
RNA linker and performing 50RACE as standard, but
instead of performing two rounds of PCR to detect a
product on a gel, the ﬁnal round was performed as
real-time PCR incorporating a molecular beacon probe
spanning the junction between the RNA linker sequence
and the 50-end of the cleaved mRNA, and termed this
method MBRACE (Figure 1). Molecular beacon probes
give a ﬂuorescent signal only when hybridised to an exact
complement, so even if multiple products were generated
by PCR, only the cDNA template from cleaved target
mRNA ligated to the RNA linker should be detected.
The method was tested ﬁrst on two ApoB clones of
known sequence generated from a prior 50-RLM-RACE
experiment using a siRNA speciﬁc for ApoB called
ApoB-1 (12): one clone was the expected product with
the RNA linker attached to the ApoB-1-directed siRNA
cleavage site; the second clone contained a 4-nucleotide
insertion between the linker and the cleavage site
(Figure 2A). MBRACE reactions were performed and as
shown in Figure 2B, only the speciﬁc product (cloned
positive) gave a ﬂuorescent signal whereas the clone with
the 4bp insertion (cloned negative) showed only the back-
ground ﬂuorescence.
The MBRACE assay is speciﬁc to the siRNA
target gene and target site
The method was further tested on a number of in vitro
samples. RNA prepared from Hepa1-6 cells transfected
with ApoB-1 or a control siRNA was initially analysed
by RT–qPCR to conﬁrm knockdown of mRNA
(Figure 2C) then tested in the standard 50-RLM-RACE
method, with two rounds of PCR prior to analysis by
agarose gel electrophoresis (Figure 2D). RT–qPCR
showed clear knockdown of ApoB transcript with
ApoB-1 siRNA (a and b, Figure 2C) compared to the
control siRNA (c and d, Figure 2C). In 50-RLM-RACE
analysis, the predicted product of 290bp was clearly
evident in cells treated with ApoB-1 siRNA (lanes a
and b, Figure 2D). A band of the correct size was also
observed in the sample from cells treated with 1nM
control siRNA (lane d, Figure 2D). This underlies the
drawback of analysing 50-RLM-RACE products based
on size alone, the identity of which must be conﬁrmed
by cloning and sequencing. To test the MBRACE
method, the products from the ﬁrst round
50-RLM-RACE PCRs were then used as template in
molecular beacon-containing real-time PCR reactions
(Figure 2E). Only the samples transfected with ApoB-1
siRNA showed a ﬂuorescent signal, whereas there was
no ampliﬁcation with the control siRNA samples. These
data demonstrate that the true product of ApoB-1
siRNA-mediated cleavage was only present in cells
transfected with the ApoB-1 siRNA and that the other
products observed by gel electrophoresis following
standard 50-RLM-RACE were artefacts not derived
from siRNA-cleaved ApoB.
The speciﬁcity of the MBRACE protocol was next
tested for the ability to detect speciﬁc cleavage of two
further mRNA species each targeted with two diﬀerent
siRNAs. A549 cells were transfected with siRNA speciﬁc
for either of three independent sites in the RRM1
(RRM1-2, RRM1-3 and RRM1-15) and one site in the
YBX1 transcript (YBX1-9). RT–qPCR experiments
demonstrated that all four siRNAs were highly eﬀective
in inducing knockdown of their target mRNA
(Figure 3A–D insets). When real-time PCR was per-
formed using molecular beacons speciﬁc to each of the
siRNA cleavage sites, a ﬂuorescent signal was detected
only with the molecular beacon speciﬁc for that siRNA
cleavage site (Figure 3A–D). Conﬁrming the speciﬁcity of
the MBRACE reaction, each molecular beacon produced
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derived from cells treated with the matching siRNA.
This is clearly evident in Figure 3C and D, where the
addition of a molecular beacon speciﬁc for the
RRM1-15-mediated cleavage resulted in a ﬂuorescent
signal only when the template was derived from A549
cells treated with RRM1-15 siRNA, and was not
detected following treatment with YBX1-9 siRNA.
Likewise, the molecular beacon complementary to the
cleavage site induced by YBX1-9 siRNA only produced
a ﬂuorescent signal when used with template from
YBX1-9 siRNA-treated cells.
Real-time PCR and 50-RLM-RACE are limited in their
eﬀectiveness for detection of cleaved mRNA in vivo
To test the ability of MBRACE to conﬁrm siRNA-
mediated knockdown in vivo, hydrodynamic tail-vein
injection (HTVI) of ApoB-1 siRNA was carried out.
Twenty-four hours after delivery of siRNA for ApoB or
mis-matched control, mice livers were harvested and RNA
prepared. These were processed for analysis by real-time
RT–qPCR to measure ApoB mRNA knockdown, and by
50-RLM-RACE to detect the presence of the speciﬁcally
cleaved mRNA fragments. In four mice receiving the
ApoB-1 siRNA, RT–qPCR analysis showed that knock-
down of ApoB was minimal (Figure 4A, A1, A2, A4 and
A7), whilst the remaining three mice in this group had
ApoB mRNA levels that were reduced by about
30–50%. To detect the presence of cleaved ApoB tran-
script, standard 50-RLM-RACE was performed. Agarose
gel electrophoresis of the 50-RLM-RACE products
showed a correct sized band (290bp) within a smear
(Figure 4B). Interestingly, two of the three mice showing
the greatest mRNA knockdown also had a clearly detect-
able band of around 290bp, which is the size predicted
following cleavage by ApoB-1 siRNA (Figure 4A and 4B,
A3 and A6). A number of other ApoB-1 samples appeared
to show increased staining in that region of the gel, but so
too did the control samples treated with mismatched
siRNA.
MBRACE detects ApoB-1 siRNA activity in vivo
The in vivo samples from Figure 4 were tested in a
MBRACE assay, using the same 50–RLM-RACE
ﬁrst-round PCR samples as template. These results
showed that RNA isolated from mice receiving the
ApoB-1 siRNA gave a positive ﬂuorescent signal, higher
than that observed with the mismatch control siRNA
Figure 1. Comparison of 50-RLM-RACE and MBRACE methods. The initial steps are the same in both methods, in which an RNA linker
(striped bar) is attached to siRNA-cleaved mRNA (solid line). After cDNA synthesis by reverse transcription, a ﬁrst round PCR reaction is set
up using one primer speciﬁc for the linker sequence and a second primer speciﬁc to the gene target and product generated (dotted line). For
standard 50RACE (left), a second round PCR is performed using internal primers (Nested). Products are then analyzed by agarose gel
electrophoresis, and amplicons of the predicted size are excised, cloned and sequenced to conﬁrm that the product is derived from
siRNA-mediated cleavage. For MBRACE, the ﬁrst round PCR products are also used as template for a second round with the same nested
primers, but the addition of a molecular beacon spanning the junction between the linker and cleaved mRNA enables ampliﬁcation to be
detected in real-time using a LightCycler 480.
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ciﬁcally cleaved ApoB product. Samples from ApoB-
1-treated mice that showed no detectable knockdown by
real-time PCR or gel electrophoresis gave a ﬂuorescent
signal, conﬁrming that some speciﬁc cleavage of the
ApoB transcript had occurred (compare Figure 4 with
Figure 5A). This was conﬁrmed by analysing two addi-
tional HTVI experiments by MBRACE, where all samples
derived from mice that were treated with the ApoB-1
siRNA showed speciﬁcally cleaved ApoB mRNA
detected by the molecular beacon probe (Figure 5B
and C). This was particularly clear in one experiment,
where even though from RT–qPCR analysis ApoB
mRNA was reduced by only 10% in one sample
(Figure 5C, A1), the MBRACE method clearly detected
the ApoB-1 siRNA-cleaved product above the mismatch
control samples.
DISCUSSION
The use of siRNA in vivo remains hampered by oﬀ-target
eﬀects and diﬃculties associated with conﬁrming that the
observed mRNA knockdown is the result of an
RNAi-mediated event. When tested in vitro, knockdown
of target mRNA by siRNA is generally eﬀective and can
be detected easily with real-time PCR, as the majority of
cells are transfected and mRNA levels are often decreased
by over 90%. Similarly, the speciﬁcity of siRNA-mediated
knockdown observed in vitro can be conﬁrmed with
50-RLM-RACE ampliﬁcation and sequencing to deter-
mine target-site cleavage, a simple albeit time-consuming
and labour-intensive process. We have used molecular
beacon probes as a tool to aid detection of
siRNA-mediated knockdown in both in vitro and in vivo
studies. The stem-loop-based hybridisation speciﬁcity of
molecular beacons has seen their application in a variety
of ﬁelds, for example utilizing their ability to give real-time
results for the provision of genetic identiﬁcation of single
nucleotide diﬀerences (19,20), as well as their use in
real-time monitoring of gene expression in isothermic
ampliﬁcation strategies (24). We found that using molec-
ular beacon probes to detect speciﬁc cleavage of mRNA
in vitro dramatically increased the speed at which we were
able to conﬁrm siRNA-mediated cleavage of the target
mRNA.
The MBRACE method was applied to ﬁve siRNAs
across three genes and in each case speciﬁcally detected
the siRNA-mediated cleavage of the mRNA. This con-
ﬁrmed the initial results obtained with the cloned ApoB
RACE products and demonstrates the broad applicability
of this method to rapid detection of siRNA-mediated
mRNA cleavage events. Using the Premier Biosoft molec-
ular beacon probe designer for our cleavage sites of
interest generated probes with moderate to high predicted
activity in each instance. Although this may vary for other
B
E D C
A
Figure 2. Speciﬁc detection of mRNA cleavage products with MBRACE in vitro.( A) Schematic representation of sequences of: (1) the RNA linker
(blue); (2) ApoB cleavage site; (3) positive (RNA linker ligated to cleavage product) and (4) negative (4bp insertion between linker and mRNA
fragment underlined) clones; and (5) the molecular beacon probe used to detect linker ligation to the cleaved mRNA fragment (red text represents the
7-bp stem). (B) Ampliﬁcation curves showing ﬂuorescent signal generated from positive (ﬁlled square) and negative (open square) cDNA clones.
(C) RT–qPCR analysis of ApoB mRNA in Hepa1-6 cells transfected with either 1 (a) or 10nM (b) ApoB-1 siRNA, or 1 (c) or 10nM (d) mismatch
control siRNA. (D) The same samples were used as template in standard 50-RLM-RACE analysis, and analyzed by electrophoresis. The correct
product indicated by the arrow has a size of 290bp. (E) Ampliﬁcation curves from MBRACE reactions using the template from siRNA-treated cells
as in (C) ﬁlled symbols represent samples transfected with ApoB-1 siRNA, and open symbols are samples transfected with mismatch control siRNA
at 10nM (open square) or 1nM (open triangle). All MBRACE experiments were performed in duplicate, but for clarity only a single, representative
replicate is shown.
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cases, the method could be further optimised by altering
the sequence of the RNA linker. Interestingly, the eﬃ-
ciency of cleavage site detection by the molecular
beacon was not always equivalent. The molecular
beacon speciﬁc for the cleavage of RRM1 mRNA
induced by siRNA RRM1-3 was notable in that the
log-linear phase of ampliﬁcation appeared much later
(>20 cycles) compared with the other target sites
(all around 10 cycles). Diﬀerences in Cp between diﬀerent
targets even within the same gene are to be expected at
this point. Although the knockdown of mRNA for both
RRM1-2 and RRM1-3 siRNAs is very similar, the
sensitivity of each cleaved mRNA to subsequent deg-
radation may diﬀer subtly leading ultimately, after two
rounds of PCR, to the diﬀerence in ampliﬁcation seen
in the MBRACE assay; also the primer combinations
after reverse transcriptase treatment are speciﬁc for
each target region, and may not be optimal with the
general reaction conditions used. Similarly, a dose
response was observed in knockdown with the YBX1-9
siRNA, but this was not reﬂected in the Cp and total
ﬂuorescence of the MBRACE assay, which was simi-
lar at all siRNA concentrations for each site. This is
likely due to the template for MBRACE being
derived from the ﬁrst round of RACE PCR, an
end-point assay. Therefore, subsequent real-time PCR
ampliﬁcations will likely begin with templates of similar
concentration, and will not reﬂect the original diﬀerences
in mRNA concentration.
After optimizing the MBRACE reaction in vitro,w e
applied this to the in vivo knockdown of ApoB mRNA
in mouse livers using a previously published siRNA
sequence (12). To overcome the need for cholesterol con-
jugation or a delivery vehicle to introduce siRNA into the
liver, we used the HTVI, one of the few methods for
introducing foreign nucleic acids in vivo without the
requirement of a delivery vehicle (25). HTVI involves
the injection of a large bolus volume (9% of body
weight) containing the nucleic acid molecule into the tail
vein over a short space of time; although injected nucleic
acid can be subsequently found in many organs, the bulk
is transferred to the liver (25–27) due to this organ having
more access to the vena cava, which takes up the injected
volume, and a non-selective entry into hepatocytes (26).
HTVI has frequently been used in siRNA in vivo studies
(28,29). However, the large volumes used have been shown
to cause some damage to cell structure, and the loss of cell
viability within the liver (30), suggesting that a decrease in
gene expression following HTVI-based delivery of siRNA
may be due to non-speciﬁc degradation of RNA following
cell death, rather than siRNA-induced RNAi. This further
AB
D C
Figure 3. Application of MBRACE assay to other targets in vitro.
MBRACE assays of RNA extracted from A549 cells transfected with
(A) 1nM and 100nM of RRM1-2, (B) 1nM and 100nM of RRM1-3,
(C) 10nM YBX1-9 or (D) 10nM RRM1-15. Filled symbols are samples
transfected with RRM1 or YBX1 siRNAs; open symbols are from cells
only control samples. YBX1 and RRM1 templates in (C) and (D) were
tested with speciﬁc molecular beacon primers and probes (ﬁlled square)
and also tested with molecular beacon primers and probes speciﬁc for
RRM1-15 (ﬁlled triangle) and YBX1-9, (ﬁlled triangle), respectively.
Inset graphs show siRNA-mediated mRNA knockdown using the
same siRNAs as measured by RT–qPCR.
A
B
Figure 4. ApoB knockdown and detection of mRNA cleavage prod-
ucts in mouse liver. (A) qRT–PCR of ApoB mRNA levels from
the livers of mice treated with ApoB-1 siRNA or a mis-matched
control siRNA by the HTVI method. Levels of ApoB mRNA were
normalised to the average of the mis-match siRNA samples.
(B) Standard 50-RLM-RACE of the same samples, analyzed by
electrophoresis on a 3% TAE-agarose gel using 1kb Plus ladder
(Invitrogen). An in vitro positive control (+ve) was prepared and
analyzed in parallel; the band of correct size (290bp) is indicated
with an arrow.
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knockdown results from an siRNA-mediated cleavage
event.
The ApoB-1 siRNA sequence used in these studies has
been used successfully in a number of previous studies.
Soutschek et al. (12) used cholesterol-conjugated siRNA
and achieved 50% knockdown of ApoB in mice, con-
ﬁrmed by 50-RLM-RACE. Cleavage products were also
detected when cholesterol-conjugated siRNA were
bound to high density or low density lipoprotein that
were subsequently perfused through mouse livers (13); in
this case the subsequent 50-RLM-RACE PCRs were
radio-labelled to increase sensitivity. Both studies
showed that decreases in liver ApoB mRNA levels of
 50%, were followed by signiﬁcant decreases in serum
levels of apolipoprotein B. This indicates that the level
of knockdown we observed using HTVI is comparable
to that seen with the diﬀerent delivery methods
employed in these studies. In comparison, when the
same ApoB-1 siRNA was delivered with stable nucleic
acid lipid particles (SNALPs), expression was decreased
to 10% at 2.5 mg/kg both in mice and in non-human
primates (16). Again, this knockdown was conﬁrmed by
50-RLM-RACE (15).
Apart from the studies listed above, conﬁrmation of the
cleavage of speciﬁc mRNA sequences directed by the
siRNA is not commonly reported. This may be due to
the diﬃculty of amplifying a clean RACE product for
latter sequencing, or the diﬃculty in delivering to organs
other than the liver. The imaging of the RACE prod-
uct can be improved with the use of radiolabelled
(10,13) or digoxygenin-labelled primers (18), or by using
radiolabelled probes speciﬁc to the ampliﬁed product (11),
whereas two rounds of nested RACE reactions were suf-
ﬁcient to generate RACE products when knockdown was
more eﬀective (16). SNALP used as a delivery vehicle was
also highly eﬀective with in vivo studies on polo-like kinase
1( Plk1) and kinase spindle protein (Ksp) in mouse hepatic
tumours, achieving 45% knockdown in expression and
being conﬁrmed with one round of 50-RLM-RACE (17).
The results of these in vivo studies suggests that more eﬀec-
tive knockdown leads to more eﬃcient ampliﬁcation of a
positive 50-RLM-RACE product. Nevertheless, when
MBRACE assays were performed following the delivery
of the ApoB-1 siRNA to mouse livers using HTVI,
evidence of speciﬁc cleavage was observed even in cases
where knockdown as measured by real-time PCR was
negligible. In three independent studies real-time RT–
qPCR analysis consistently showed at best 30–50%
knockdown of ApoB mRNA, and even with this level of
knockdown clear 50-RLM-RACE results were not
obtained. However, MBRACE results for the samples
showed signiﬁcantly more ﬂuorescence than seen in
negative control samples indicating the presence of the
speciﬁcally-cleaved ApoB transcript. These results con-
ﬁrmed not only the successful delivery of the ApoB-1
siRNA but also that RNAi-mediated cleavage of the
target had indeed occurred. These results further demon-
strate the sensitivity, combined with the inherent
speciﬁcity, of the MBRACE method and its utility in the
analysis of in vivo experiments.
The development of siRNAs for clinical use is being
pursued for an ever widening range of targets, making it
all the more surprising, with the precedent set by the
studies described earlier, that it is still rare to see conﬁr-
mation that an siRNA-mediated eﬀect observed in vivo
has indeed occurred via RNAi. Two recent reports
included RACE data at thein vitro stage of development
to validate the activity of the siRNA used. A study target-
ing the neurotensin receptor 2 (NTS2) mRNA with a
27-mer dicer-substrate siRNA used 50RACE both to
ensure that the 27-mer employed was diced to the active
21-mer siRNA, as well as to conﬁrm that the excised
siRNA cleaved the target NTS2 mRNA at the predicted
site (31). Similarly, 50RACE was used to show that
b1,3-D-glucan-encapsulated siRNA particles mediated
knockdown of the targeted mRNA of mitogen activated
kinase kinase kinase kinase 4 (Map4k4) (32). Neither
study, however, applied 50RACE methodology to sub-
sequent in vivo experiments, and successful 50RACE
detection from in vitro samples does not necessarily
mean that the subsequent knockdown of the target
mRNA observed in vivo also results from an RNAi-
mediated cleavage event.
A more surprising trend in recently published reports is
the absence of RACE data altogether. Instead, many
reports describingthe successful application of siRNA in
in vivo studies still present real-time RT–qPCR results
without conﬁrmatory RACE data (33–38). Some do not
measure thedecrease in the target mRNA at all, and
instead usemeasurements of just the protein target, the
disease phenotype or tumour size (39–41). While all of
these studies show activity of siRNA in vivo, they lack
the demonstration of a biological link between the
observed phenotypic eﬀects and the activation of the
RNAi machinery by the delivered siRNA. In light of
reports demonstrating that the immune stimulatory
properties of siRNAs can lead to some of the eﬀects
observed when siRNAs are administered in vivo (6,7),
we suggest that incorporation of 50RACE-based
methodologies become a requirement for the publication
of studies applying siRNA in vivo. Our results demon-
strate that the incorporation of a molecular beacon
speciﬁc to the siRNA-mediated cleavage site during
the second round of RACE in a real-time PCR set-
ting enables speciﬁc, rapid and sensitive detection of
cleaved mRNA in vivo. Employing this methodology
to future studies of RNAi in vivo will help to clarify the -
relative importance of speciﬁc and non-speciﬁc
eﬀects caused by administration of siRNAs in animal
models of metabolic disease, cancer and viral infection
without recourse to time-consuming cloning and
sequencing steps.
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